Colin Macaulay
Founder at Viron Therapeutics, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
James Moodie Rae | M | - |
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | 17 years |
Robert Browne | M | - |
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Bill James Peck | M | 64 |
University of Alberta
| - |
Grant McFadden | M | - |
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | 19 years |
Ronald Kisic | M | - |
University of Alberta
| 8 years |
R. Allford | M | - |
University of Alberta
| 8 years |
Neil Warma | M | 61 |
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | 3 years |
Bruce Beynon | M | 60 |
University of Alberta
| 6 years |
Christian Bayle | M | 55 |
University of Alberta
| 5 years |
Miles W. Safranovich | M | - |
University of Alberta
| 9 years |
Raymond Bower | M | - |
University of Alberta
| 4 years |
Kevin V. Sullivan | M | 49 |
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | 10 years |
Dale Hildebrand | M | 60 |
University of Alberta
| 7 years |
Kris Smith | M | - |
University of Alberta
| 4 years |
Terry Caelli | M | - |
University of Alberta
| 7 years |
Kam Lun Eric Ng | M | 63 |
University of Alberta
| 4 years |
Cameron R. Fink | M | 55 |
University of Alberta
| 4 years |
John Williams | M | 72 |
University of Alberta
| 4 years |
Tammy DuPerron | F | 63 |
University of Alberta
| 4 years |
David Anderson | M | 54 |
University of Alberta
| 4 years |
Steven James Glover | M | - |
University of Alberta
| 2 years |
Keung Jimmy Chik Wong | M | - |
University of Alberta
| 4 years |
Paul Kristensen | M | - |
University of Alberta
| 4 years |
John Bossio | M | 55 |
University of Alberta
| 4 years |
Da Li Zhang | M | 64 |
University of Alberta
| 1 years |
Kar Loon Quek | M | 61 |
University of Alberta
| 4 years |
Jeffrey Green | M | - |
University of Alberta
| 4 years |
Ben Nyland | M | 54 |
University of Alberta
| 4 years |
Darrell Cotterill | M | - |
University of Alberta
| 4 years |
Bruno Kasper | M | - |
University of Alberta
| 4 years |
Tom Peterson | M | - |
University of Alberta
| 4 years |
Bruce N. Moisey | M | 62 |
University of Alberta
| 4 years |
Scott Carter | M | - |
University of Alberta
| 4 years |
Dwayne William Sorobey | M | 59 |
University of Alberta
| 4 years |
Lisa Doig | F | - |
University of Alberta
| 4 years |
Stephanie Sterling | F | 57 |
University of Alberta
| 4 years |
Conan Taylor | M | - |
University of Alberta
| 4 years |
Russell Edward Wlad | M | - |
University of Alberta
| 4 years |
Martin Vydra | M | - |
University of Alberta
| 3 years |
Richard Roy | M | - |
University of Alberta
| 4 years |
Michael Power | M | - |
University of Alberta
| 4 years |
Kwok Hay Wong | M | 75 |
University of Alberta
| 3 years |
Jugdutt Singh | M | - |
University of Alberta
| 1 years |
Troy G. Tews | M | - |
University of Alberta
| 4 years |
Steve Dobler | M | 60 |
University of Alberta
| 4 years |
Bryce Kremnica | M | - |
University of Alberta
| 4 years |
Doyle Sam | M | - |
University of Alberta
| 4 years |
Louis Picco | M | 58 |
University of Alberta
| 4 years |
Louis Hugo Francescutti | M | - |
University of Alberta
| 3 years |
Michèle Stanners | F | 66 |
University of Alberta
| 3 years |
Arokia Nathan | M | - |
University of Alberta
| 3 years |
Wendy Henkelman | F | 59 |
University of Alberta
| 4 years |
Doug McMillan | M | - |
University of Alberta
| 4 years |
Gregory F. Juneau | M | 57 |
University of Alberta
| 4 years |
Dean Schultz | M | - |
University of Alberta
| 4 years |
Antoinette Boquiren | F | 56 |
University of Alberta
| 4 years |
Michael J. Rusch | M | 78 |
University of Alberta
| 4 years |
Tony Bright | M | - |
University of Alberta
| 4 years |
John Williamson | M | 64 |
University of Alberta
| 4 years |
Terry Tucker | M | - |
University of Alberta
| 4 years |
Philip Collins | M | - |
University of Alberta
| 4 years |
Shane Ebert | M | - |
University of Alberta
| 4 years |
Robert James Maddigan | M | - |
University of Alberta
| 4 years |
Stuart Olley | M | - |
University of Alberta
| 2 years |
Norm A. Gretzinger | M | - |
University of Alberta
| 4 years |
Kerry Kozlowski | F | - |
University of Alberta
| 4 years |
Douglas Bartole | M | 56 |
University of Alberta
| 4 years |
Wendell Zerb | M | 60 |
University of Alberta
| 4 years |
Don Rawson | M | - |
University of Alberta
| 4 years |
Allan Gregory Stepa | M | - |
University of Alberta
| 4 years |
Patrick Stiles | M | - |
University of Alberta
| 4 years |
Mark G. Maybank | M | 53 |
University of Alberta
| 5 years |
Bruce Daniel Beingessner | M | 59 |
University of Alberta
| 4 years |
Robert Foster | M | 65 |
University of Alberta
| 9 years |
Garey James Aitken | M | - |
University of Alberta
| 4 years |
Changxin Li | M | 63 |
University of Alberta
| 3 years |
Sean W. Duffee | M | - |
University of Alberta
| 4 years |
Gordon Robert McCormack | M | 59 |
University of Alberta
| 4 years |
Thorsten Brost | M | - |
University of Alberta
| 4 years |
Michael R. Smillie | M | - |
University of Alberta
| 4 years |
Cheryle Donahue | F | - |
University of Alberta
| 4 years |
John Haylock | M | - |
University of Alberta
| 4 years |
Gregory Francis Kennedy | M | 74 |
University of Alberta
| 4 years |
Cary Pothorin | M | - |
University of Alberta
| 4 years |
Ross McElroy | M | 60 |
University of Alberta
| 4 years |
Monroe Thomas | M | - |
University of Alberta
| 4 years |
Darin Labrenz | M | 58 |
University of Alberta
| 4 years |
Mark Krantz | M | - |
University of Alberta
| 4 years |
Darren Gee | M | 56 |
University of Alberta
| 4 years |
Gregory J. Hansen | M | 58 |
University of Alberta
| 4 years |
Craig Hruska | M | - |
University of Alberta
| 4 years |
Jeffrey G. Sheremeta | M | 52 |
University of Alberta
| 4 years |
Sean M. Brett | M | 58 |
University of Alberta
| 5 years |
Donald Boykiw | M | - |
University of Alberta
| 3 years |
Kevin J. Inman | M | - |
University of Alberta
| 4 years |
Shaun E. Alspach | M | - |
University of Alberta
| 4 years |
Arie B. Prins | M | - |
University of Alberta
| 4 years |
George Chow | M | 62 |
University of Alberta
| 3 years |
Darin R. Coutu | M | 58 |
University of Alberta
| 4 years |
Leanne Geale | F | 59 |
University of Alberta
| 4 years |
Statistics
Country | Connections | % of total |
---|---|---|
Canada | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Colin Macaulay
- Personal Network